Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion by Jūratė Barysienė et al.
RESEARCH ARTICLE Open Access
Findings of transoesophageal
echocardiogram in appropriately
anticoagulated patients with persistent
atrial fibrillation prior to planned
cardioversion
Jūratė Barysienė1,2, Aistė Žebrauskaitė1,2* , Dovilė Petrikonytė1,2, Germanas Marinskis1,2, Sigita Aidietienė1,2
and Audrius Aidietis1,2
Abstract
Background: To evaluate a diagnostic value of transoesophageal echocardiogram (TEE) in appropriately anticoagulated
patients with a non-valvular atrial fibrillation (AF) and to establish possible additional indications for TEE; to evaluate the
incidence of left atrial (LA) thrombi in appropriately anticoagulated patients in daily clinical practice.
Methods: This retrospective study analyses data of 432 patients who had been anticoagulated by means of oral
anticoagulants (OACs) prior to planned cardioversion during the period from 2012 to 2015. Thromboembolic (TE) and
bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Transthoracic and transoesophageal
echocardiograms were evaluated. TE complications during 30 days after discharge were assessed.
Results: 432 patients were selected, aged from 22 to 89 years (mean 65.0 ±11.5), 277 (64.1%) males and 155
(35.9%) females, 306 (70.8%) on warfarin and 126 (29.2%) on non-vitamin K antagonist oral anticoagulants (NOAC).
Mean CHA2DS2-VASc score was 3.5 ±1.5. TEE was performed for 120 (27.8%) patients, more frequently for patients on
NOACs and for ones with III° LA enlargement.
TEE revealed LA thrombi in seven (5.8%) of the patients. In warfarin and NOACs groups thrombi were revealed in five
(7.0%) and two (4.1%) patients, respectively. TEE did not reveal any thrombi in patients with normal left ventricular (LV)
function; however, thrombi were found in two (6.1%) patients with slightly decreased LV function, and in five (17.9%)
patients with markedly decreased LV function.
In patients with decreased left ventricular ejection fraction (LVEF) thrombi in LA were found more frequently than in
patients with normal and slightly decreased LVEF (17.9% vs 2.2%, p=0.008). CHA2DS2-VASc score of all 7 patients was ≥5.
None of the patients after cardioversion had TE complications 30 days after discharge.
Conclusions: The risk of LA thrombi in patients prepared for scheduled cardioversion in line with the guidelines is low.
Higher risk of thrombi was present in patients with decreased LVEF (≤40%), CHA2DS2-VASc ≥5. In order to assess more
accurately indications to perform TEE for appropriately anticoagulated patients prior to scheduled cardioversion a study
with larger number of patients is required.
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Background
Atrial fibrillation (AF) is the most common long-lasting
supraventricular arrhythmia [1]. In order to improve the
condition of patients suffering from symptomatic per-
sistent AF, restoration of sinus rhythm (SR) can be
performed.
Ischemic stroke is the most common complication of
AF, with the risk remaining high if prophylaxis of
thromboembolic (TE) complications is not administered.
AF is the cause of every fourth/fifth ischemic stroke and
mortality of these strokes is two times higher in com-
parison with other types of ischemic stroke [1, 2].
Oral anticoagulants (OACs) may reduce the risk of AF
related ischemic stroke by 60 – 80%. The risk of TE
complications increases during restoration of SR [1].
The incidence of TE events in patients who were not
treated with OACs before restoration of SR ranges from
5 to 7% [3], while in patients appropriately prepared for
scheduled cardioversion, the incidence of these compli-
cations can be decreased to 1.0% [4, 5].
To prevent TE complications before scheduled SR restor-
ation vitamin K antagonists (VKA) [1, 6] or non-vitamin K
antagonist oral anticoagulants (NOACs) are administered
[1, 6]. Transoesophageal echocardiogram (TEE) for detec-
tion of intracardiac thrombi can be performed in order to
assess the efficacy of anticoagulation therapy or as an alter-
native for treatment with OACs [1, 6].
Furthermore, changes of pharmacogenomics of drugs
action are more frequent in patients taking VKA. Actu-
ally, only two thirds of the patients on warfarin achieve
the therapeutic international normalized ratio (INR)
interval for > 64% of period required [7].
Therefore, the duration of preparation for scheduled
cardioversion lasts from two to three months [8, 9]. The
action of NOACs is stable, dosage is simple, preparation
for scheduled SR restoration is shorter. On the other
hand, some patients do not comply even with this sim-
plified NOAC administering schedule [10]. This is why
physicians have doubts concerning the reliability of
anticoagulation before scheduled cardioversion and they
perform additional TEE.
The aims of this retrospective study are to evaluate the
expedience of TEE before cardioversion in patients
properly anticoagulated with OACs suffering from per-
sistent non-valvular AF; to assess the incidence of detec-
tion of intracardiac thrombi; to evaluate risk factors of
thrombi formation, and to establish additional indica-
tions for administering TEE before scheduled SR restor-
ation procedure.
What’s new?
In patients with atrial fibrillation appropriately prepared
with oral anticoagulants for scheduled cardioversion, risk
of thromboembolic complications remains below 1.0%,
with the incidence of asymptomatic left atrium thrombi
up to 7.7% [11, 12]. The aim is to establish clinical cri-
teria of appropriately anticoagulated patients who are at
higher risk of thromboembolic complications and for
whom transoesophageal echocardiogram would be bene-
ficial before sinus rhythm restoration.
The higher risk of cardiac thrombi is in patients with
decreased left ventricular ejection fraction (≤40%),
CHA2DS2-VASc ≥ 5.
Methods
This retrospective study was performed at the Centre of
Cardiology and Angiology at Vilnius University Hospital
Santariskiu Clinics and included patients who were
≥18 years old, suffering from non-valvular AF and who
were prepared for scheduled SR restoration using OACs.
During the period from October 2012 to November
2015, 2940 patients underwent scheduled electrical car-
dioversion. 2987 patients underwent TEE; this number
included 567 patients with persistent non-valvular AF
who were prepared for direct current cardioversion
(DCC) using OACs; 432 patients were properly anticoa-
gulated and included into this study. The data were ob-
tained from Hospital electronic database, out-patient
and in-patient case files. The study was approved by
local Bioethics committee.
AF without moderate or high degree stenosis of mitral
valve or presence of mechanical valve prosthesis was
considered to be non-valvular. Prior to scheduled cardio-
version, the patients for ≥3 weeks used NOACs (dabiga-
tran, rivaroxaban, apixaban) or warfarin, maintaining
documented INR 2.0-3.0, for not less than 3 subsequent
weeks. Individual dosing of NOAC drugs was done ac-
cording to recommendations. Since it is difficult to con-
firm directly that patients are indeed taking NOACs
properly, we considered to have patients’ verbal confirm-
ation and signature in hospital file confirming that she/
he did not miss the dosage.
The following criteria were evaluated: patient age, sex,
body mass index (BMI), concomitant diseases (arterial
hypertension (AH), diabetes mellitus (DM), heart failure
(HF), former stroke or transient ischemic attack (TIA),
coronary artery disease (CAD). The risk of ischemic
stroke and systemic embolism was evaluated using
CHA2DS2-VASc scale [13], the risk of bleeding was
assessed using HAS-BLED scale [14].
Left ventricular hypertrophy (LVH), size of left atrium
(LA) and left ventricular ejection fraction (LVEF) were
assessed using trans-thoracic echocardiography. LVH
was diagnosed if interventricular septum and posterior
left ventricle (LV) wall thickness equaled or exceeded
11 mm [15]. The size of LA was assessed according to
atrial volume in 4-chamber view: no enlargement
22–58 ml, I° enlargement 59–68 ml, II° enlargement
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69–78 ml, III° enlargement ≥79 ml [15]. LV systolic func-
tion was evaluated by LVEF: normal ≥50%, slightly de-
creased 41–49%, decreased ≤40% [16]. TEE was
performed in 120 patients. TEE was performed more
frequently for patients on NOACs because of insufficient
confidence and experience of physicians with these
drugs, also because it was not possible to check the ef-
fect of the drug. The decision to perform TEE was made
on the assumption of the physicians that expected risk
of TE complications was higher. HF or IIIº LA enlarge-
ment, especially their combination, were considered as
main factors influencing decision to perform TEE. All
patients were studied using Philips iE33 ultrasound ma-
chine. All TEE images obtained in each patient were re-
corded as movie images on a digital media for display
and evaluation in real time. TEE images of the LA and
left atrium appendage (LAA) were evaluated in the hori-
zontal (0°) plane and in the plane at rotation of the im-
aging sector (0°–180°) during continuous visualization of
the LAA. Thrombus was defined as an echo-dense, well-
circumscribed, uniformly consistent mass with a texture
different from that of the LAA wall. If thrombi were
present, DCC was not performed.
All the study patients for whom scheduled DCC was
performed were interviewed by phone 30 days after res-
toration of SR, in order to reveal TE complications.
Statistical analysis. The data were processed using SPSS
20 and Microsoft Excel software, Pearson’s chi square tests
were applied and standard deviations (SD) were calculated
for the mean values.
Results
The total number of the patients with non-valvular AF
prepared for scheduled SR restoration using OACs was
567. Appropriate anticoagulation was not achieved in
135 patients and the data of these patients were not in-
cluded into subsequent analysis. Appropriate anticoagu-
lation for scheduled DCC was achieved in 432 patients
and the data of these patients were analyzed. The
scheme of patients distribution is shown in Fig. 1.
The age of the patients ranged from 22 to 89 years,
mean age was 65.1 ± 11.5 years. There were 277 (64.1%)
male and 155 (35.9%) female patients. The mean age of
male and female patients was 61.8 ± 11.9 and 70.5 ±
8.1 years, respectively.
The majority of the patients were suffering from
AH (92.4%), HF (76.4%) and CAD (50.5%). Decreased
LV systolic function was present in 18.3% and LA
enlargement was observed in 83.1% of the patients.
The distribution of the patients in accordance with
demographic data, stroke, TE and bleeding risk,
echocardiography findings and concomitant diseases
is presented in Table 1.
Warfarin and NOACs were administered for 306
(70.8%) and 126 (29.2%) patients, respectively. In
NOACs group 74 (58.7%) patients were on dabigatran,
39 (31.0%) were on rivaroxaban and 13 (10.3) were on
apixaban.
Warfarin was administered for the patients in
whom the risk of TE complications and bleeding was
higher (CHA2DS2-VASc 3.6 (SD ± 1.6) vs 3.4 (SD ± 1.5),
p = 0.058); HAS-BLED ≥ 3 (5.6% vs 4.8% p = 0.08).
For males and elderly (>75 years) patients NOACs
were administered more frequently (30.3% vs 27.1%, p =
0.27 and 25.4% vs 20.3%, p = 0.27, respectively). In pa-
tients with good LV systolic function, administration of
NOACs was more frequent (61.1% vs 46.4%, p < 0.001)
and when LV EF was ≤ 40% administration of warfarin
was more common (21.2% vs 11.1%, p < 0.001). When
there was no LA enlargement, NOACs were adminis-
tered more frequently (25.4% vs 13.4%, p = 0.008), but if
LA was enlarged treatment by warfarin was usually pre-
ferred (74.6% vs 86.6%, p = 0.008). Patients with the his-
tory of stroke or TIA were prepared for restoration of
SR with warfarin more frequently (6.9% vs 1.6%, p =
0.013). Almost one-third of the patients properly pre-
pared for SR restoration (n = 120, 27.8%) underwent
TEE before the procedure. This investigation was more
frequently performed for the patients treated with
NOACs (n = 49, 38.9% vs n = 71, 23.2%, p < 0.001).
Detailed characteristics of the groups of the patients are
presented in Table 2.
The total score of CHA2DS2-VASc, HAS-BLED and pa-
tient age had no influence on decision to perform TEE
(see Table 3). TEE was performed more frequently for pa-
tients with enlargement of LA III° (32.5% vs 21.8%, p =
0.01) and suffering from HF (81.7 vs 74.4%, p = 0.068).
TEE revealed LA thrombi in 7 (5.8%) patients, in 5
males and 2 females (71.4% and 28.6%, respectively). In
these patients SR was not restored, treatment with
OACs was continued. The patients’ age ranged from 44
to 84 years (mean age 64.1 ± 14.9). CHA2DS2-VASc
score in these patients ranged from 5 to 7 points.
Thrombi were found in 2 (6.1%) of patients with slightly
decreased LV function and in 5 (17.9%) of patients with
markedly decreased LV function. In patients with de-
creased LVEF thrombi in LA were found more fre-
quently than in patients with normal and slightly
decreased LVEF (17.9 vs 2.2%, p = 0.008). Decreased LV
systolic function and CHA2DS2-VASc score ≥5 were ob-
served in all male patients. In both female patients LV
systolic function was slightly decreased and CHA2DS2-
VASc score was 6. Thrombi were detected in 5 (7.0%)
patients of warfarin group and in 2 patients (4.1%) of
NOACs group. The duration of the preparation period
for the scheduled restoration of SR in patients with LA
thrombi in warfarin group was longer in comparison
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with the period in NOACs group (2 – 24 months, mean
11.4 months vs 3 – 8 weeks, mean 6 weeks). A previous
history of LA thrombi was found in two male patients,
and SR was restored after prolonged anticoagulagion
and repeated TEE. After the next AF relapse, TEE re-
vealed LA thrombi again, anticoagulation was prolonged
and TEE repeated. One patient did not have LA
thrombi, SR was restored and the patient is waiting for
LA appendage closure. Another patient still has LA
thrombi, and permanent AF was diagnosed. For other 3
patients TEE was repeated after 1 and 3 months,
thrombi in LA remained and permanent AF with OAC
treatment and rate control was continued. For 2 patients
TEE was repeated after 1 month, thrombi in LA resolved
and SR was restored, with no TE complications 30 days
after cardioversion. In both groups the presence of
thrombi did not depend on the grade of LA enlargement.
An interview by phone was performed 30 days after
restoration of SR. There were no TE complications in
patients four weeks after discharge.
Discussion
The aim of our study was to assess the diagnostic value
of TEE in patients with non-valvular AF anticoagulated
according to guidelines, and to establish possible add-
itional indications for TEE and to evaluate incidence of
LA thrombi in properly anticoagulated patients in daily
clinical practice. In our study this incidence is similar to
other studies’ data, in which thrombi in LA were found
for 3.6–7.7% patients properly anticoagulated with war-
farin before scheduled cardioversion [11, 12]. We found
LA thrombi in 7.0% patients in warfarin group and 4.1%
in NOACs group, we cannot state that risk of thrombo-
embolism is higher in the warfarin group, because the
number of these patients is small and because of men-
tioned selection bias. It should be noted that the number
of patients on warfarin was larger and the duration of
preparation for scheduled DCC of patients in whom LA
thrombi were revealed lasted longer, in comparison with
those in NOACs group, with duration ranging from 2 to
24 months (mean 11 months) vs 3-8 weeks (mean
6 weeks), respectively. The prolonged duration of prep-
aration possibly had an influence on thrombi formation
as well.
It is not obligatory to perform TEE for patients prop-
erly prepared for DCC by OACs [1, 6]. However, if a
physician has any concerns regarding compliance to
OAC treatment, or for other reasons that may influence
the formation of intracardiac thrombi before scheduled
DCC, it is reasonable to perform TEE [6, 17]. In RE-LY
study the duration of dabigatran administration before
scheduled DCC was ≥3 weeks. In the group of patients
Fig. 1 Scheme of patient selection and distribution. DCC – direct current cardioversion, LA – left atrium, NOACs – non-vitamin K antagonist oral
anticoagulants, TEE - transoesophageal echocardiography
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who received 110 mg of dabigatran twice daily, TEE was
performed for 25.5%. LA thrombi were detected in 1.8%
of these patients. In the group of patients who received
150 mg of dabigatran twice daily, TEE was performed in
24.1% of the cases and LA thrombi were detected in
1.2% of the patients [18]. In ARISTOTLE study, for pa-
tients prepared for scheduled DCC with apixaban, TEE
was performed for 36.6% of the patients and no LA
thrombi were found. However, the treatment duration
prior to restoration of SR was long (251 ± 248 days) [19].
The question whether the treatment with NOACs last-
ing from 3 to 4 weeks is sufficient to prepare the patient
for scheduled DCC remains an object for discussion.
The study of dabigatran demonstrated that preparation
for scheduled DCC for 4 weeks is safe [20] but the prob-
lem of compliance with the treatment still remains. The
half-life of NOACs (about 12 hours) is markedly shorter
in comparison with warfarin; therefore, missing of a dose
at the appropriate time results in the rapid decrease of
anticoagulation action. The patients comply with the
treatment of NOACs better than these on warfarin, but
the accuracy of use of preparations is not clear. During a
one-year period of observation, 47.5% of the patients re-
ceiving NOACs compared to 40.2% of the patients on
warfarin, complied with the treatment for 80% of obser-
vation period (p < 0.001) [10]. In order to assure appro-
priate use of the drug, more strict control is required.
This is why additional TEE is being performed, even in
patients properly prepared with OACs for planned SR
restoration [1, 6, 9]. We did not find any relationship be-
tween the decision to perform TEE and the estimated
CHA2DS2-VASc score. The age of the patient was not
considered as a decisive factor to carry out TEE.
Approximately half of the patients (49.2%) who under-
went TEE were younger than 65 years.
Table 1 Distribution of the patients according to demographic
data, echocardiography findings, stroke, thromboembolic and
bleeding risk stratification, concomitant diseases
Patients Warfarin group NOACs group
(n, %) (n, %) (n, %)
Male 277 (64.1%) 193 (63.1%) 84 (66.7%)
Female 155 (35.9%) 113 (36.9%) 42 (33.3%)
Age, years ± SD 65.1 ± 11.5 64.6 ± 11.1 64.9 ± 12.5
CHA2DS2-VASc value ± SD 3.5 ± 1.5 3.6 ± 1.6 3.4 ± 1.5
HAS-BLED value ± SD 0.9 ± 0.9 1.1 ± 0.9 0.9 ± 0.9
HF 330 (76.4%) 238 (77.8%) 92 (73.0%)
AH 399 (92.4%) 280 (91.5%) 119 (94.4%)
CAD 216 (50.0%) 164 (53.6%) 52 (41.3%)
Previous stroke or TIA 23 (5.3%) 21 (6.9%) 2 (1.6%)
DM 54 (12.5%) 41 (13.4%) 13 (10.3%)
BMI 18.5 – 24.9 kg/m2 59 (14.5%) 39 (13.5%) 20 (16.8%)
BMI 25.0 – 29.9 kg/m2 138 (33.9%) 95 (33.0%) 43 (36.1%)
BMI ≥30 kg/m2 209 (51.4%) 153 (53.0%) 56 (47.0%)
LVH 29 (6.7%) 19 (6.2%) 10 (7.9%)
LVEF ≥50% 219 (50.7%) 142 (46.4%) 77 (61.1%)
LVEF 41–49% 134 (31.0%) 99 (32.4%) 35 (27.8%)
LVEF ≤40% 79 (18.3%) 65 (21.2%) 14 (11.1%)
No LA enlargement 73 (16.9%) 41 (13.4%) 32 (25.4%)
I° LA enlargement 126 (29.2%) 91 (29.7%) 35 (27.8%)
II° LA enlargement 126 (29.2%) 94 (30.7%) 32 (25.4%)
III° LA enlargement 107 (24.8%) 80 (26.1%) 27 (21.4%)
Total 432 (100%) 306 (70.8%) 126 (29.2%)
BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, HF
heart failure, LA left atrial, LVEF left ventricular ejection fraction, LVH left
ventricle hypertrophy, NOACs non-vitamin K antagonist oral anticoagulants, SD
standard deviation, TIA transient ischemic attack
Table 2 Distribution of the patients in accordance with decision
to perform TEE, with demographic data, thromboembolic and
bleeding risk stratification, echocardiography findings and
concomitant disease
TEE performed
(n, %)
TEE not performed
(n, %)
Male 77 (64.2%) 200 (64.1%)
Female 43 (35.8%) 112 (35.9%)
On warfarin 71 (23.2%) 235 (76.8%)
On NOACs 49 (38.9%) 77 (61.1%)
Mean age, years ± SD 63.5 ± 11.1 65.2 ± 11.6
CHA2DS2-VASc value ± SD 3.5 ± 1.5 3.6 ± 1.6
HAS-BLED value ± SD 1.1 ± 1.0 1.0 ± 0.8
HF 98 (81.7%) 232 (74.4%)
AH 113 (94.2%) 288 (91.7%)
CAD 54 (45.0%) 162 (51.9%)
Previous stroke or TIA 8 (6.7%) 15 (4.8%)
DM 16 (13.3%) 38 (12.2%)
BMI <25 kg/m2 13 (11.1%) 47 (16.2%)
BMI 25,0 – 29,9 kg/m2 47 (40.2%) 91 (31.4%)
BMI ≥30 kg/m2 60 (49.6%) 152 (52.4%)
LVH 7 (5.8%) 22 (7.1%)
LVEF ≥50% 59 (49.2%) 160 (51.3%)
LVEF 41-49% 33 (27.5%) 105 (33.7%)
LVEF ≤40% 28 (23.3%) 47 (15.1%)
No LA enlargement 19 (15.8%) 54 (17.3%)
I° LA enlargement 24 (20.0%) 102 (32.7%)
II° LA enlargement 38 (31.7%) 88 (28.2%)
III° LA enlargement 39 (32.5%) 68 (21.8%)
Total 120 (27.8%) 312 (72.2%)
BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, HF
heart failure, LA left atrial, LVEF left ventricular ejection fraction, LVH left ventricle
hypertrophy, NOACs non-vitamin K antagonist oral anticoagulants, SD standard
deviation, TEE transoesophageal echocardiography, TIA transient ischemic attack
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In our study, more than a half of the patients (55.2%)
were obese (BMI ≥30 kg/m2). Obesity increases the risk
of development of a new AF, the incidence of AF re-
lapses and the risk of development of permanent AF. In
obese patients with AF, the decrease of the weight reli-
ably decreases the incidence of AF relapses and total
duration of the episodes [21]; on the other hand, there
are controversial data if obese patients with AF have an
increased risk of TE events. According to our data, this
factor had no influence on the incidence of AF relapses,
the decision to perform TEE, or the detection of heart
chamber thrombi.
Male and elderly patients received NOACs more
frequently in our study. Warfarin was more frequently
administered to the patients with a higher risk of TE
complications and history of stroke or TIA. The inci-
dence of NOACs administration was higher for patients
with normal systolic LV function, without LA enlarge-
ment, while patients with decreased LVEF or LA
enlargement received warfarin more frequently.
The majority of patients (73.9%; p = 0.087) with a high
risk of bleeding (HAS-BLED ≥3) used warfarin. For pa-
tients who had a high TE risk (CHA2DS2-VASc ≥6) only
warfarin was administered. Warfarin was more fre-
quently administered to the patients suffering from
CAD, possibly because of ESC 2015 Guidelines recom-
mending exclusive prescription of warfarin as a part of
triple anticoagulation therapy after acute coronary syn-
dromes or scheduled percutaneous transluminal coron-
ary angioplasty. TEE was performed in NOACs group
more frequently, in comparison with the warfarin group
(38.9 vs 23.2%).
In the study performed by Zylla et al. [17] 643 patients
with non-valvular AF and prepared for scheduled DCC
by VKA and NOACs were evaluated. TEE was per-
formed for all study subjects. The mean CHA2DS2-
VASc score was 4. LA thrombi were detected in 10.6%
of the patients and the incidence of thrombi was higher
in the warfarin group (17.8 vs 3.9%). In patients for
whom TEE revealed thrombi they had a higher
CHA2DS2-VASc score (4–5 points in 49%), larger LA or
suffered from LV systolic dysfunction. The incidence of
thrombi detected was higher in patients treated by VKA
with intra-cardiac devices (pacemakers, defibrillators),
suffering from CAD. The patients in NOACs group were
younger, had a lower CHA2DS2-VASc score, less dilated
LA, and better LV systolic function; the incidence of
NOACs administration was lower for patients with
intra-cardiac devices implanted. The data of our study
are quite similar. LA thrombi were revealed in 7 (5.8%)
of patients properly prepared using OACs for SR restor-
ation. We found out that the mean CHA2DS2-VASc
score was 3.5, but the sample of patients with 4 points
was the largest (24.5%). In the case when the CHA2DS2-
VASc score was ≥6, only warfarin was administered. The
patients on NOACs were younger in our study and they
also had less concomitant diseases. However, in patients
>75 years old NOACs were administered more frequently,
possibly because of difficulties in monitoring INR while
administering warfarin, and INR lability.
Similarly, to the data of Zylla et al. [17], in our study
the incidence of LA thrombi was higher in warfarin
group. Patients in whom intracardiac thrombi were re-
vealed had a higher CHA2DS2-VASc score, and de-
creased LV systolic function. In two patients who had
history of LA thrombi TEE revealed newly formed ones.
Both of these patients were on warfarin and their
CHA2DS2-VASc score was 6.
The risk of TE complications in the event of markedly
decreased LV systolic function (LV EF < 35%) in females
is two times higher, in comparison with the risk in males
[22]. However, the incidence of thrombi in males,
according to our data, is two times higher.
In our study, an interview by phone 30 days after res-
toration of SR showed no TE complications.
This retrospective study was based on everyday clinical
practice and demonstrated that even for patients properly
prepared for SR restoration, TEE was performed quite
Table 3 Distribution of patients who had and did not have TEE, in accordance with CHA2DS2-VASc and HAS-BLED risk scores
CHA2DS2-VASc score
0 1 2 3 4 5 6 7 8
TEE was performed
(n, %)
0
0%
9
7.5%
26
21.7%
23
19.2%
32
26.7%
19
15.8%
8
6.7%
3
2.5%
0
0%
TEE was not performed
(n, %)
5
1.6%
21
6.7%
65
20.8%
58
18.6%
74
23.7%
55
17.6%
27
8.7%
6
1.9%
1
0.3%
HAS-BLED score
0 1 2 3 4
TEE was performed
(n, %)
42
35.0%
42
35.0%
26
21.7%
7
5.8%
3
2.5%
TEE was not performed
(n, %)
95
30.4%
140
44.9%
64
20.5%
12
3.8%
1
0.3%
TEE transoesophageal echocardiography
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extensively. The risk of thrombi formation, when the pa-
tient is prepared by OACs for restoration of SR and ad-
equate anticoagulation is achieved, is low but still remains.
Therefore, in all cases the risk for a patient should be eval-
uated individually.
Limitations
The number of patients in whom LA thrombi have been
identified is small (n = 7). It is necessary to perform lar-
ger studies of properly anticoagulated patients to make
firm conclusions.
Conclusions
The risk of LA thrombi in patients who are prepared for
scheduled SR restoration according to guidelines is low.
The higher risk of cardiac thrombi was present in pa-
tients with decreased LVEF (≤40%), CHA2DS2-VASc ≥5.
A larger number of patients is required, in order to as-
sess more precise TEE indications for properly anticoa-
gulated patients prior to scheduled cardioversion.
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